NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Wuxi Pharma Tech back to previous page show list

Wuxi Pharma Tech

»
address: Address:

288 FuTe ZhongLu
WaiGaoQiao Free Trade Zone
Shanghai 200131, China
contact: Tel: +86(21)5046-1111

Fax: +86(21)5046-1000

www.pharmatechs.com
key person: Chairman and Chief Executive Officer - Ge Li, Ph.D.
Chief Scientific Officer
Shuhui Chen, Ph.D.
Chief Manufacturing Officer
Suhan Tang, Ph.D.


Vice President, Analytical Services
Ning Zhao, Ph.D.

trunover in millions USD: 135
R & D turnover in millions USD: 0
NET profit: 34
year of financial results: 2007
employees: 0

active in China: YES
partner in China: also at Tianjin

SFDA approved: YES
SFDA approved date: 30/03/2007
Address & Contact Details: Also at Tianjin

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: YES
New materials Safety Assessment: YES
Pharmaceuticals: YES
Agrochemicals: NO
Industrial & Other Chemicals: YES
Non GLP - Discovery ADME: YES

Chemistry-contract manufacture:
Generics: NO
API: YES
Licensed Drugs: NO

test:
R&D: YES
 

Founded in 2001, Shanghai-based WuXi PharmaTech is China¡¯s leading drug R&D service company. As a research-driven and customer-focused company, WuXi PharmaTech offers global pharmaceutical and biopharmaceutical companies a diverse, value-added, and fully integrated portfolio of outsourcing services ranging from discovery chemistry to GMP manufacturing.

WuXi PharmaTech assists its global partners in shorting the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions. Our management team consists of many "returnees" that bring experience from top pharmaceutical and biopharmaceutical firms of the US, Japan, and India.

With nearly 1,400 scientific staff members, a 680,000 sq. ft. Shanghai WaiGaoQiao Free Trade Zone research facility, a 250,000 sq. ft. GMP manufacturing plant, and a soon to be online 130,000 sq. ft. state-of-the-art Tianjin research facility, WuXi PharmaTech is positioned to offer its collaborative partners unparalleled depth and quality of service. Currently, WuXi PharmaTech¡¯s clientele list consists of 19 of the top 20 pharmaceutical, and 8 of the top 10 biopharmaceutical companies.

 

WuXi PharmaTech (Cayman) Inc., and its consolidated subsidiaries, WuXi PharmaTech (BVI) Inc., or WXPT BVI, WuXi PharmaTech Co., Ltd., or WXPT, Shanghai PharmaTech Co., Ltd., or SHPT, Shanghai SynTheAll Pharmaceutical Co., Ltd., or STA, Shanghai PharmaTech Chemical Technology Co., Ltd., or SHCT, Tianjin PharmaTech Co., Ltd., or TJPT, and Suzhou PharmaTech Co., Ltd., or SZPT;

They are engaged in a substantial capacity expansion program. Major projects include the expansion of Jinshan facility to quadruple the manufacturing capacity of the plant, which is currently expected to commence operations in late 2008, and the construction of a preclinical drug safety evaluation center with a broad range of toxicology services in Suzhou, which they are planning to inaugurate in 2009. These facilities may not be constructed on the anticipated timetable or within budget.

The total investment of Suzhou Pharmatech (a subsidiary of Wuxi Pharmatech) is 60,000,000 US Dollars, it will run as the research center of drug safety evaluation, preclinical and clinical trials, besides these, this center provides the drug research service, medical material and R&D of bio-products.


company map(s):

company map(s): Wuxi Pharma Tech

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.